Replies to post #82411 on Biotech Values

[mcbio]

Re: BPAX/LibiGel

I don’t agree. To the contrary, I think LibiGel has a good chance to be a big-selling drug.

Are you surprised that BPAX hasn't been able to land a lucrative partnership for the drug yet given the large opportunity? Has there been any buzz on recent conference calls about any pending partnership? A tiny market cap (~$50 million) plus a potential big-selling drug is always an equation to pique my interest in a stock so I may take a closer look at this one.

[genisi]

PG/Intrinsa, BPAX

Don't think anyone has mentioned the fact that PG signed a license agreement with NOVN for a 2nd generation transdermal patch for HSDD, think about a year ago.